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Interleukin (IL)-22 is a cytokine displaying tissue protective and pro-regenerative
functions in various preclinical disease models. Anti-bacterial, pro-proliferative, and anti-
apoptotic properties mediated by activation of the transcription factor signal transducer
and activator of transcription (STAT)-3 are key to biological functions of this IL-10 family
member. Herein, we introduce RINm5F insulinoma cells as rat β-cell line that, under
the influence of IL-22, displays activation of STAT3 with induction of its downstream
gene targets Socs3, Bcl3, and Reg3b. In addition, IL-22 also activates STAT1 in this cell
type. To refine those observations, IL-22 biological activity was evaluated using ex vivo
cultivated murine pancreatic islets. In accord with data on RINm5F cells, islet exposure
to IL-22 activated STAT3 and upregulation of STAT3-inducible Socs3, Bcl3, and Steap4
was evident under those conditions. As these observations supported the hypothesis
that IL-22 may exert protective functions in toxic β-cell injury, application of IL-22 was
investigated in murine multiple-low-dose streptozotocin (STZ)-induced diabetes. For
that purpose, recombinant IL-22 was administered thrice either immediately before and
at disease onset (at d4, d6, d8) or closely thereafter (at d8, d10, d12). These two IL-
22-treatment periods coincide with two early peaks of β-cell injury detectable in this
model. Notably, none of the two IL-22-treatment strategies affected diabetes incidence
or blood glucose levels in STZ-treated mice. Moreover, pathological changes in islet
morphology analyzed 28 days after disease induction were not ameliorated by IL-22
administration. Taken together, despite being active on rat RINm5F insulinoma cells
and murine pancreatic islets, recombinant IL-22 fails to protect pancreatic β-cells in
the tested protocols from toxic effects of STZ and thus is unable to ameliorate disease
in the widely used model of STZ-induced diabetes.
Keywords: streptozotocin-diabetes, RINm5F cells, tissue regeneration, tissue protection, STAT3 transcription
factor, IL-22
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INTRODUCTION
Interleukin (IL)-22 (Dumoutier et al., 2000) is a member of
the IL-10 cytokine family that, based on cell-type restricted
expression of its heterodimeric IL-10R2/IL-22R1 receptor,
primarily acts on non-leukocytic foremost epithelial (like-) cells.
Notably, whereas IL-10R2 is ubiquitous, IL-22R1 expression
adheres to aforementioned restrictions (Wolk et al., 2004).
IL-22 biological activity is tightly connected to activation of
signal transducer and activator of transcription (STAT)-3, albeit
eﬃcient and functionally decisive STAT1 signaling is possible
in context speciﬁc manner, particularly under the inﬂuence
of interferons (IFN; Bachmann et al., 2013; Mühl, 2013;
Hernández et al., 2015; Lamarthée et al., 2015). In most cases,
however, IL-22 biological properties mirror STAT3 actions which
characteristically include strengthening of anti-apoptotic and
pro-proliferative cellular processes as well as enforcing cellular
stress resistance in general (Aujla and Kolls, 2009; Wolk et al.,
2010; Kong et al., 2013; Dudakov et al., 2015). Accordingly, on
the one hand IL-22 has been shown to promote carcinogenesis
(Lim and Savan, 2014; Waidmann et al., 2014) but, on the other
hand, is likewise capable to serve protective and pro-regenerative
tissue functions in the context of diverse toxic insults (Mühl et al.,
2013). Disease models in which IL-22 application has been shown
to ameliorate tissue damage in face of toxic challenges include
acute liver injury in response to acetaminophen (Scheiermann
et al., 2013; Feng et al., 2014) or alcohol (Xing et al., 2011),
colitis induced by dextran sulfate sodium (Cox et al., 2012), and
cerulein-induced pancreatitis (Feng et al., 2012).
Streptozotocin (STZ) is a glucosamine-nitrosourea that acts
by alkylating DNA and exposing cells to reactive oxygen species
and nitric oxide (Szkudelski, 2001; Lenzen, 2008). Due to
expression of the Glut-2 glucose transporter, STZ eﬃciently
accumulates in rodent pancreatic β-cells resulting in cell death, a
mechanism routinely deployed to induce experimental diabetes.
Speciﬁcally, administration of multiple-low-doses of STZ to mice
mediates initial early β-cell apoptosis followed by leukocytic
inﬁltration into the pancreas amplifying pathogenesis with
subsequent development of diabetic symptoms (O’Brien et al.,
1996; Cardinal et al., 2001; Barlow et al., 2004; Fukuda et al.,
2008).
Herein, we set out to investigate eﬀects of IL-22 on rodent
pancreatic β-cells. To assess tissue protective properties of IL-
22 concerning β-cell survival and stress robustness in vivo,
recombinant cytokine was administered during the critical
initiation phase of multiple-low-dose STZ-induced diabetes.
MATERIALS AND METHODS
Reagents
Recombinant murine IL-22 was purchased from Immunotools
(Friesoythe, Germany). Rat IL-22 was from R&D Systems
(Frankfurt, Germany). Rat IL-6 was from Peprotech Inc.
(Hamburg, Germany). Staurosporine and STZ were from Sigma-
Aldrich (Taufkirchen, Germany).
Cultivation of RINm5f Cells and Primary
Murine Islets
RINm5F Insulinoma cells (ATCC, Wesel, Germany) were
maintained in RPMI 1640 supplemented with 100 U/ml
penicillin, 100 μg/ml streptomycin (Life Technologies,
Darmstadt, Germany), and 10% heat-inactivated FCS (Biochrom,
Berlin, Germany) at 37◦C and 5% CO2. For experiments, cells
were seeded on 6-well and 96-well polystyrene plates (Greiner,
Frickenhausen, Germany) in aforementioned culture medium.
Murine islets of Langerhans were isolated from wildtype
C57Bl/6J mice and cultured at 37◦C and 5% CO2 in RPMI 1640
supplemented with 100 U/ml penicillin, 100μg/ml streptomycin,
1% non-essential amino acids, 1% pyruvate (Life Technologies),
and 10% heat-inactivated FCS (Biochrom). Brieﬂy, the pancreas
was dissected and perfused with collagenase P solution (1.2 U/ml
in RPMI 1640, Roche Applied Science, Mannheim, Germany).
Islets were isolated by density gradient centrifugation using
Ficoll Paque Plus (GE Healthcare, München, Germany), were
washed, and handpicked thereafter. Isolation by combined
density gradient centrifugation and subsequent handpicking as
performed herein results in highly pure cultures with islet
purity >99% (Ramírez-Domínguez and Castaño, 2015). After
48–96 h recovery in aforementioned medium, 60–100 islets (as
speciﬁed in the respective ﬁgure legends) were seeded on 12-well
polystyrene plates (Greiner, Frickenhausen).
Detection Of Il22r1 And Il10r2mRNA by
Standard Polymerase Chain Reaction
(PCR)
Total RNA, isolated by Tri-Reagent (Sigma–Aldrich,
Taufkirchen, Germany) or NucleoSpin RNA XS columns
(RNA from islets, Macherey and Nagel, Düren, Germany) was
transcribed using random hexameric primers and Moloney virus
reverse transcriptase (Life Technologies). The following sequence
was performed for each PCR reaction: IL-22R1 and IL-10R2,
95◦C for 10min (1 cycle); followed by 95◦C for 30 s, 60◦C for 30s,
and 72◦C for 1min (39 cycles); followed by a ﬁnal extension phase
at 72◦C for 7 min. The following primers were used: mouse IL-
22R1, forward: 5′-GTGGAATATAAGAAATACGGAGAGAG-3′
and reverse: 5′-TTCAAGGTGCATCTGGTAGGTG-3′; mouse
IL-10R2, forward: 5′-GGGACTAATGAGAAGTTTCAAGTTG-
3′ and reverse: 5′-CCAGAAACTCCTTCAGGTGC-3′; rat
IL22R1, forward: 5′-TGCCCGATCGGACGTGG-3′ and
reverse: 5′-GGCTGCACCTCAGGGAG-3′; rat IL10R2,
forward: 5′-TGGAAGACACCATTATCGGACC-3′ and reverse:
5′-GGGAGGGGTTGTTTCATCAC-3′. The possibility of
ampliﬁcation of contaminating genomic DNA was eliminated
by selecting amplicons that cross exon/intron boundaries. PCR
products (murine IL-22R1, 379 bp; murine IL-10R2, 268 bp; rat
IL-22R1, 420 bp; rat IL-10R2, 337 bp) were run on a 1.5% agarose
gel containing 0.5 μg/ml ethidium bromide.
Detection of Socs3, Bcl3, Steap4, and
Reg3b mRNA by Realtime PCR
During realtime PCR, changes in ﬂuorescence are caused
by the Taq polymerase degrading the probe that contains
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FIGURE 1 | RINm5F cells are IL-22 responsive. (A) Untreated rat RINm5F cells were analyzed for expression of IL-22R1 and IL-10R2 mRNA by standard-PCR.
cDNA obtained from rat Morris hepatoma cells and murine kidney adenocarcinoma Renca cells served as positive and negative control, respectively. Murine IL-22R1
mRNA is not detected by rat specific primers. One representative of three independently performed experiments is shown. (B) RINm5F cells were kept as
unstimulated control, or stimulated with IL-22 (as indicated) or IL-6 (10 ng/ml) for 30 min. Whole cell lysates were analyzed for phospho-STAT3 by Westernblot
analysis. After stripping the same blots were analyzed for total STAT3. One representative of three independently performed experiments is shown. (C) To investigate
STAT3 activity, RINm5F cells were co-transfected with SIE-luciferase reporter- and CMV-renilla-plasmids. After transfection, cells were either kept as unstimulated
controls or were stimulated with IL-22 or IL-6 (both 10 ng/ml) for 3 h. Thereafter, luciferase firefly activity was determined relative to renilla. Mean relative luciferase
activity is expressed as fold-induction compared to unstimulated control ± SD (n = 4); ∗∗p < 0.01 compared with unstimulated control, ##p < 0.01. Raw data were
analyzed by one-way ANOVA with post hoc Bonferroni correction. (D) RINm5F cells were kept as unstimulated control or stimulated with IL-22 (as indicated) for
30 min. Whole cell lysates were analyzed for phospho-STAT1 by Westernblot analysis. After stripping, the same blots were analyzed for total STAT1. One
representative of three independently performed experiments is shown.
a ﬂuorescent dye [VIC, glycerinaldehyd-3-phosphate-
dehydrogenase (GAPDH); all others: FAM; Life Technologies].
Pre-developed assay reagents (Life Technologies) were used for
target gene analysis: Bcl3 Rattus norvegicus Rn01457652_m1,
Gapdh R. norvegicus 4352338E, Reg3b R. norvegicus
Rn00583920_m1, Socs3 R. norvegicus Rn00585674_s1, Bcl3
Mus musculusMm00504306_m1,Gapdh M. musculus 4352339E,
Steap4 M. musculus Mm00475405_m1, Socs3 M. musculus
Mm00545913_s1. Assay-mix was from Life Technologies.
Realtime PCR was performed on AbiPrism7500 Fast Sequence
Detector (Life Technologies): two initial steps at 50◦C for 2 min
and at 95◦C for 20 s were followed by 40 cycles at 95◦C for 3 s
and 60◦C for 30s. Detection of the dequenched probe, calculation
of threshold cycles (Ct values), and data analysis were performed
by the Sequence Detector software. Relative changes in mRNA
expression compared to unstimulated control and normalized to
Gapdh were quantiﬁed by the 2−ddCt method.
Detection of Stat1 and Stat3 by
Westernblot Analysis
Whole cell lysates were generated from RINm5F cell and
islet cultures (Bachmann et al., 2007) as well as from liver
tissue (Scheiermann et al., 2013) and subjected to Westernblot
analysis using protocols previously described. For detection of
total STAT1 or total STAT3, blots were stripped and reprobed.
Antibodies: pSTAT1-Y701 (reacts against rat and murine
pSTAT1), rabbit polyclonal antibody (Cell Signaling, Frankfurt,
Germany, catalog #9171); pSTAT3-Y705 (reacts against rat and
murine pSTAT3), rabbit polyclonal antibody (Cell Signaling,
catalog #9145); total STAT1, rabbit polyclonal antibody (reacts
against rat STAT1, Cell Signaling, catalog #9172); total STAT3
(reacts against rat and murine STAT3), mouse monoclonal
antibody (Cell Signaling, catalog #9139).
Cell Death Analysis
RINm5F cells (1.5 × 104/well) were seeded on 96-well
polystyrene plates. After 24 h of cultivation, cells were stimulated
as speciﬁed. Cytotoxicity was determined based on lactate
dehydrogenase release using the CytoTox 96 non-radioactive
cytotoxicity assay kit (Promega, Mannheim, Germany) according
to the manufacturer’s instructions.
Transfection of RINm5f Cells and
Luciferase Reporter Assays
1 μg per conﬂuent 6-well plate of a STAT3 luciferase reporter
designed to quantify the transcriptional activity of STAT3
[pGL4.47 luc2P-SIE (Promega); along with 0.5 μg pRL-CMV-
Renilla (Promega)] was transiently transfected into RINm5F
cells using Lipofectamine2000 (Invitrogen, Karlsruhe, Germany)
according to the manufacturer’s instructions. After 4 h of
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FIGURE 2 | Expression of STAT3 downstream target genes Socs3, Reg3b, and Bcl3 in IL-22-stimulated RINm5F cells. (A–C) RINm5F cells were kept as
unstimulated control or stimulated with IL-22 (10 ng/ml) for the indicated time periods. Thereafter, target mRNA expression was determined by realtime PCR. Socs3
(n = 4; A), Reg3β (n = 4; B), and Bcl3 (n = 3; C) mRNA was normalized to that of Gapdh and is shown as mean fold-induction compared to unstimulated
control ± SD; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001. Raw data were analyzed by unpaired Student’s t-test. (D) RINm5F cells were kept as unstimulated control or
stimulated with IL-22 (as indicated). After 3 h, Bcl3 mRNA expression was determined by realtime-PCR. Bcl3 mRNA was normalized to that of Gapdh and is shown
as mean fold-induction compared to unstimulated control ± SD (n = 3); ∗p < 0.05, ∗∗∗P < 0.001 compared with unstimulated control, ###p < 0.001. Raw data
were analyzed by one-way ANOVA with post hoc Bonferroni correction.
transfection, mediumwas exchanged and cells were cultivated for
further experiments as outlined in the ﬁgure legends. Thereafter,
cells were harvested and luciferase activity was determined using
the dual luciferase reporter assay system (Promega) and an
automated chemiluminescence detector (Glomax, 96 microplate
luminometer, Promega).
The Murine Multiple-Low-Dose (Mld)
Model of Stz-Induced Experimental
Diabetes
Experiments using male 8-week-old C57Bl/6J mice (Charles
River Laboratories, Sulzfeld, Germany) were approved by the
Regierungspräsidium Darmstadt and were in accordance with
NIH guidelines. Mice were sacriﬁced, and organs were either
snap frozen in liquid nitrogen and stored at −80◦C. Pancreata
were immersed in Tissue-Tek OCT (Sakura Finetek, Alphen,
Netherlands) and quick-frozen on dry ice.
Recombinant murine IL-22 (Immunotools, Friesoythe,
Germany) dissolved in PBS was administered i.p. (3.5 μg per
mouse and injection). Equal volumes of PBS served as control.
To assess IL-22 bioactivity, selected mice were sacriﬁced 30 min
after administration and liver tissue was analyzed for STAT3
activation by Westernblot analysis.
To induce diabetes, mice were injected i.p. with multiple
low doses of STZ (5 mg × 55 mg STZ/kg body weight) on
ﬁve consecutive days (days 1–5). STZ was dissolved in 10 mM
citric acid buﬀer (pH 4.5) and injected within 5 min. Solvent
treated mice served as controls. STZ control groups received PBS
injection on days 8, 10, and 12. IL-22 was administered either on
days 4, 6, and 8 (protocol-1) or on days 8, 10, and 12 (protocol-
2) as outlined in the ﬁgure legends. After 28 days, mice were
sacriﬁced.
Determination of Blood Glucose Levels
Blood samples were obtained from the tail vein. Blood
glucose was monitored with a OneTouch Ultra (LifeScan,
Neckargemünd, Germany) twice weekly in unfasted mice.
Animals with blood glucose values over 300 mg/dL on two
consecutive days were considered diabetic.
Immunohistochemistry
Using cryomicrotome and sialin-coated Superfrost Plus slides
(Langenselbold, Germany), 7 μm tissue sections of immersed
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FIGURE 3 | Ex vivo cultivated murine islets are IL-22 responsive. (A) Islet expression of murine IL22R1 and IL10R2 mRNA was analyzed by standard PCR.
One representative of three independently performed experiments is shown. cDNA from rat RINm5F cells served as negative control (neg. ctrl). Rat IL-22R1 mRNA is
not detected by murine specific primers. One representative of three independently performed experiments is shown. (B) Islets were kept as unstimulated controls or
stimulated with IL-22 (100 ng/ml). After 30 min, whole cell lysates were analyzed for phospho-STAT3 by Westernblot analysis. After stripping the same blots were
analyzed for total STAT3. One representative of three independently performed experiments is shown. (C–E) Islets were kept as unstimulated controls or stimulated
with IL-22 (20 ng/ml). After the indicated time periods, target mRNA expression was determined by realtime PCR. Socs3 (n = 6; C), Bcl3 (0.5 h/3 h: n = 6, 1 h:
n = 8; D), and Steap4 (0.5 h/3 h: n = 6, 1 h: n = 7; E). mRNA was normalized to that of Gapdh and is shown as mean fold-induction compared to unstimulated
control ± SEM; ∗p < 0.05, ∗∗p < 0.01. Raw data were analyzed by unpaired Student’s t-test.
pancreata were cut. Sections were then ﬁxed with 4% PFA
and, after washing in PBS, an avidin/biotin-blocking step was
included (Vector Laboratories, Peterborough, UK). Primary and
biotinylated secondary antibodies (Vector Laboratories) were
incubated with the sections for 60 min each. Color reaction
was obtained by sequential incubation with avidin-peroxidase
conjugate (Vector Laboratories) and diaminobenzidine-
hydrogen peroxide (Vector Laboratories). Antibodies: polyclonal
guinea pig anti-murine insulin (Dako, Glostrup, Denmark) and
biotinylated rat α-guinea pig (Vector Laboratories). Sections
were counterstained using hematoxylin (AppliChem, Darmstadt,
Germany).
Statistical Analysis
Data are shown as means± SD or as means± SEM (as indicated)
and presented as fold-induction, mg/dL, or as %, [cytotoxicity,
diabetes incidence, (area > 20000 mm2)]. For data presentation
mean ± SD is chosen in case of experiments using the cell line
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FIGURE 4 | Administration of recombinant IL-22 fails to modulate incidence and course of disease in multiple-low-dose STZ-induced diabetes. Male
C57BL/6 mice were treated with citric acid [ctrl-group black lines in (A–D), n = 9] or five times daily with 55 mg/kg STZ (days 1–5). Those STZ-treated mice were, as
indicated below, subdivided in three further groups. STZ-only [blue lines in (A–D), n = 14] obtained for control reasons i.p. PBS on days 8, 10, and 12.
STZ-protocol-1 [red lines in (A,B), n = 9] obtained i.p. IL-22 (3.5 μg per mouse) on days 4, 6, and 8. STZ-protocol-2 [red lines in (C,D), n = 10] obtained i.p. IL-22
(3.5 μg per mouse) on days 8, 10, and 12. All groups were monitored for 28 days. Twice weekly, blood glucose levels were analyzed from tail vein blood. Mice were
defined diabetic if two consecutive blood glucose levels were ≥300 mg/dl. (A,C) Mean blood glucose levels are shown in mg/dl ± SEM. (B,D) Diabetes incidence is
shown in percent. ∗∗∗p < 0.001 for STZ-only versus ctrl-group at the respective time points. Raw data were analyzed by unpaired Student’s t-test.
RINm5F. In case of data involving primary cells and individual
mice mean ± SEM is shown. Statistical analysis was performed
as indicated in the legends by one-way ANOVA with post hoc
Bonferroni correction (GraphPad 5.0) or unpaired Student’s
t-test.
RESULTS
Activation of Rodent Pancreatic β-Cells
By Il-22 as Detected in RINm5f
Insulinoma Cells
Rat RINm5F insulinoma cells are an established cell culture
model for pancreatic β-cells used to study eﬀects of cytokine
activation and escalating cellular stress, such as exposure to
overt nitric oxide (Eizirik et al., 1991; Ankarcrona et al., 1994).
Herein, we introduce this β-cell line as experimental system
robustly responding on a biochemical level to activation by
IL-22. Accordingly, expression of both IL-22 receptor chains,
namely IL-10R2 and IL-22R1 (Figure 1A), as well as IL-22-
induced activation of STAT3 was readily detectable in RINm5F
cells. The latter observation became apparent by Westernblot
analysis (Figure 1B) and luciferase-reporter assays (Figure 1C),
respectively. Interestingly, activation of STAT3 by IL-6, examined
in these same experiments, was only modest as compared to that
by IL-22 (Figures 1B,C). Most cytokines initiating signaling via
STAT proteins, including IL-22, are capable of activating more
than one type of STAT (Mühl, 2013; Villarino et al., 2015). In fact,
in addition to STAT3, striking activation of STAT1 was detectable
in IL-22-activated RINm5F cells (Figure 1D).
To assess functional consequences of RINm5F cell exposure
to IL-22, prototypic STAT3-inducible genes were investigated,
namely suppressor of cytokine signaling (Socs)-3 (Hoegl et al.,
2011), B cell lymphoma (Bcl)-3 (Brocke-Heidrich et al., 2006),
and regenerating islet-derived protein (Reg)-3β (Zheng et al.,
2008; Willson et al., 2013). As shown in Figure 2, mRNA
expression of SOCS3 (A), Reg3β (B), and Bcl3 (CD) were
signiﬁcantly upregulated by IL-22 as sole stimulus. Data thus
clearly indicate functionality of the IL-22/STAT3 axis in RINm5F
cells.
Activation of Ex Vivo Cultivated Murine
Primary Islets by Il-22
To extend those observations onto the level of primary cells,
murine pancreatic islets were isolated and analyzed ex vivo. As
with RINm5F cells, expression of IL-10R2 and IL-22R1 was
readily detectable in cultured islets (Figure 3A) which agrees
with previous proof of IL-22R1 protein on human (Shioya et al.,
2008) and murine (Hasnain et al., 2014) islet β-cells. In addition,
we report that ex vivo stimulation of murine islets with IL-22
resulted in STAT3 activation (Figure 3B) and upregulation of
STAT3 downstream gene targets, speciﬁcally Socs3 (Figure 3C),
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FIGURE 5 | Administration of recombinant IL-22 fails to ameliorate pancreatic morphological changes associated with multiple-low-dose
STZ-induced diabetes. Male C57BL/6 mice were treated as indicated in legend Figure 4. After 28 days, mice were sacrificed, pancreata harvested and imbedded
for histologic analysis. (A) Cryosections were immunohistologically stained for insulin and counterstained with hematoxylin. Shown are representative of five analyzed
pancreata per group. 4x/20x = 4-fold/ 20-fold magnification. (B) Immunohistological stainings of whole pancreata were analyzed in twofold magnification. All insulin
positive areas per section were counted and evaluated by Image J. Shown are mean percentages of insulin positive areas ≥20000 μm2 ± SEM (n = 5); ∗p < 0.05,
∗∗p < 0.01 compared with citric acid-treated ctrl-group. Data were analyzed using one-way ANOVA with post hoc Bonferroni correction. n.s., not significant.
(C) Male C57BL/6 mice were either treated with PBS or 3.5 μg IL-22. After 30 min, mice were sacrificed and organs harvested. Liver lysates were analyzed for
phospho-STAT3 content by Westernblot analysis. After stripping the same blots were analyzed for total STAT3 levels. Each lane represents an individual mouse.
Bcl3 (Figure 3D), and six transmembrane epithelial antigen
of prostate (Steap)-4 (Ramadoss et al., 2010; Figure 3E). Data
presented altogether conﬁrm that murine pancreatic islets are
targets of IL-22 biological activity (Hill et al., 2013; Hasnain et al.,
2014).
Administration of Il-22 Fails to Modulate
Disease in a Protocol of
Multiple-Low-Dose Stz-Induced
Diabetes
Thorough analysis of early events in the model of multiple-
low-dose STZ-induced diabetes previously revealed two early
peaks of β-cell apoptosis at days 5 and 11 after onset of STZ
application (daily, days 1–5; O’Brien et al., 1996). Based on
this former report, two regimes of treatment with recombinant
IL-22 were investigated herein. First, IL-22 treatment on days
4, 6, and 8 after onset of STZ application (protocol-1). This
treatment period starts days before onset of disease at around
day 9 (Figure 4). Notably, aforementioned previous study did
not detect signiﬁcantly elevated rates of islet apoptosis before
day 5 (O’Brien et al., 1996). The second regime consists of IL-
22 treatment on days 8, 10, and 12 (protocol-2) thus starting
immediately at disease onset (Figure 4). Both regimes involved
three i.p. applications of recombinant murine IL-22 at a dosage
of 3.5 μg/mouse. This same dosage was previously used in our
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FIGURE 6 | Induction of death in RINm5F cells by exposure to
staurosporine or STZ is not prevented by pre-incubation with IL-22.
RINm5F cells were kept as unstimulated control or stimulated with IL-22
(10 ng/ml). After 24 h, staurosporine (500 nM) or STZ (5 mM) were added as
indicated for further 16 h. Thereafter, supernatants and cell lysates were
harvested, and cytotoxicity was determined as outlined in the section
“Materials and Methods.” Shown is the mean percent cytotoxicity ± SD
(n = 3); ∗∗p < 0.01, ∗∗∗p < 0.001; n.s., not significant. Data were analyzed by
one-way ANOVA with post hoc Bonferroni correction.
laboratory to ameliorate acetaminophen-induced liver damage
(Scheiermann et al., 2013).
As shown in Figure 4, neither IL-22 treatment protocol-1
(AB) nor protocol-2 (CD) changed onset, course, or incidence
of STZ-induced diabetes. This observation was conﬁrmed on
the morphological level by immunohistochemical analysis and
quantiﬁcation of insulin-positive pancreatic areas in animals
under investigation. Notably, STZ-induced diabetes typically
associates with a more scattered and dense appearance of insulin-
positive islets (Figure 5A). This process can be quantiﬁed
by counting the pancreatic fraction of insulin-positive islet
areas larger than 20000 μm2 (Bellenger et al., 2011). As
shown in Figure 5B, multiple-low-dose STZ treatment in fact
mediated a signiﬁcant drop in (islet area > 20000 μm2) which,
however, was not signiﬁcantly aﬀected by IL-22 treatment
protocol-1 or −2. In order to conﬁrm the biological activity
of recombinant IL-22 in vivo, STAT3 activation in liver tissue
was determined 30 min after i.p. injection of the cytokine. In
accord with previous observations (Scheiermann et al., 2013),
Westernblot analysis revealed robust activation of hepatic STAT3
in response to administration of recombinant IL-22 to mice
(Figure 5C).
Despite lacking the Glut-2 glucose transporter and thus
displaying reduced STZ sensitivity (Elsner et al., 2000), STZ is
inherently able to mediate apoptotic cell death in RINm5F cells
(Morgan et al., 1994; Koo et al., 2011) which in cell culture
proceeds toward secondary necrosis. Since IL-22 is supposed
to mediate anti-apoptosis by promoting expression of survival
genes, RINm5F cells were pre-incubated with IL-22 before
induction of cell death. In concurrence with aforementioned
in vivo data, IL-22 likewise failed to protect RINm5F cells in
culture from death under the inﬂuence of STZ. In fact, IL-22
actually enhanced cell death by STZ in RINm5F cells which
may relate to activation of inﬂammatory STAT1 in this cell type
(Figure 1D). Cells were incubated in parallel with prototypic
pro-apoptotic staurosporine serving as positive control for
induction of cell death in this cellular system (Figure 6).
DISCUSSION
The principle of IL-22 enforcing regenerative processes has
been characterized best for the liver (Ren et al., 2010; Park
et al., 2011), however, likely aﬀects various other pathological
conditions. In general, tissue protection by IL-22 is based on its
capability to initiate in STAT3-dependent manner anti-apoptotic
and mitogenic pathways (Mühl et al., 2013). Those connect to
upregulation of survivin (Xu et al., 2015), Bcl-2 and/or Bcl-XL, of
cyclin D1 and/or c-Myc (Radaeva et al., 2004; Kong et al., 2012),
and to activation of protein kinase B (Mitra et al., 2012) as well as
ERK1/2 (Lejeune et al., 2002).
To support regenerative responses at the endocrine pancreas,
speciﬁcally at the β-cell compartment, is a promising strategy
for the development of novel therapeutics targeting diabetic
diseases (Migliorini et al., 2014). Hitherto, it has become
apparent that IL-22 ameliorates pancreatic β-cell stress and
metabolic disease in murine obesity (Hasnain et al., 2014).
Direct action of IL-22 on β-cells, however, has been a matter
of debate. In fact, another study did not detect islet STAT3
activation by immunohistochemistry performed 2 h after
administration of recombinant IL-22 to mice. In contrast,
phospho-STAT3 was detectable in pancreatic acinar cells on
these same tissue sections (Park et al., 2015). However, it cannot
be excluded that this observation relates to late timing of
analysis (2 h after IL-22 application) and reduced sensitivity
of standard immunohistochemistry. Notably, albeit acinar cells
express high levels of IL-22R1 (Aggarwal et al., 2001; Gurney,
2004), the IL-22 receptor is evidently detectable on β-cells by
immunoﬂuorescence confocal microscopy of murine C57BL/6
pancreatic islets (Hasnain et al., 2014).
Herein, we introduce the rat β-cell line RINm5F as
biochemically and functionally IL-22 responsive. To assess the
role of IL-22 for the endocrine pancreas more closely to primary
cells but also biochemically standardized, experiments were
performed using ex vivo cultivated islets. Data presented indicate
functional IL-22 receptor expression by murine C57BL/6 islets.
Accordingly, activation of STAT3 was readily detectable by
Westernblot analysis after exposure of islet cultures to IL-22.
Islet STAT3 activation coincided with induction of prototypic
STAT3 downstream target genes. This observation concurs with
a previous report on IL-22 responsiveness of NOD mice-derived
islets. There, STAT3 activation was formally not investigated but
a mitogenic pro-regenerative β-cell response was observed after
ex vivo stimulation with IL-22 (Hill et al., 2013). Altogether,
data from RINm5F cells and ex vivo cultivated islets (Hill
et al., 2013 and data presented herein) as well as confocal
immunoﬂuorescence analysis of murine islets in situ (Hasnain
et al., 2014) support the view that β-cells can serve as direct IL-22
target.
Activation of rat RINm5F cells or murine pancreatic
islets by IL-22 resulted in upregulation of prototypic STAT3
inducible genes, among those interesting candidates displaying
Frontiers in Pharmacology | www.frontiersin.org 8 January 2016 | Volume 6 | Article 317
Berner et al. IL-22 Application in Streptozotocin-Induced Diabetes
an immunoregulatory or tissue protective potential at the
inﬂamed/stressed pancreas. Those include SOCS3 (Murray,
2007) which in cell culture is β-cell protective (Karlsen et al.,
2001), however, by curbing protective STAT3 signaling in vivo,
seemingly is pathogenic as detected using a β-cell-speciﬁc
knockdown during STZ-induced diabetes (Mori et al., 2007).
In addition, Bcl3 (Maldonado and Melendez-Zajgla, 2011)
was a further gene identiﬁed herein as IL-22 inducible in
pancreatic cells. Interestingly, this protein is capable of inhibiting
several inﬂammatory processes that are regarded pivotal for
autoimmune diabetes pathogenesis (Ruan et al., 2010). Similarly,
Reg3b was upregulated by IL-22 in RINm5F cells. Notably,
expression of Reg proteins has been related to pancreatic islet
regeneration (Lu et al., 2006; Hill et al., 2013). Finally, we report
for the ﬁrst time on induction of Steap4 by IL-22, a regulatory
path recognized herein inmurine islets. Steap4 is part of the β-cell
stress response program, though its exact function in that context
needs clariﬁcation (Sharma et al., 2015).
Altogether, data indicated that administration of recombinant
IL-22 may be able to ameliorate via STAT3 β-cell stress/toxicity
and consequently subsequent development of diabetes, a scenario
to be investigated in the well-deﬁned model of multiple-low-dose
STZ application (Ahn et al., 2015). In order to test this hypothesis
IL-22 treatment was intentionally conﬁned to the initial disease
phase for which early β-cell apoptosis is decisive (O’Brien et al.,
1996). By applying this speciﬁc regime, eﬀects of administered IL-
22 on subsequently established disease can be excluded. Notably,
IL-22 short-term treatment of mice is well tolerated and without
apparent immediate side eﬀects (Scheiermann et al., 2013).
Despite these thoughtful consideration, we observed that IL-22
treatment did neither aﬀect incidence nor course of multiple-
low-dose STZ-induced diabetes. Data are in accord with a very
recent report on thatmatter, albeit authors did not indicate details
of their IL-22 treatment protocol (Park et al., 2015). In vivo
data presented herein are furthermore supported by cell culture
experiments demonstrating that RINm5F cell death by STZ is not
inhibited but actually slightly increased under the inﬂuence of
IL-22.
In summary, though biologically active on islet cells in
culture, recombinant IL-22 failed to modulate disease initiation
in multiple-low-dose STZ-induced diabetes. Data presented thus
weaken the hypothesis that recombinant IL-22 can be used in
focused short-term therapy to adequately support pancreatic islet
protection and regeneration under conditions of overt β-cell
stress.
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